Sickle Cell Anemia

Disclaimer: This information is for educational purposes for healthcare professionals and does not replace clinical judgment or institutional protocols. Always consult current organizational guidelines.

---

Overview

• Definition: An autosomal recessive hemoglobinopathy characterized by the substitution of valine for glutamic acid at the sixth position of the $\beta$-globin chain (HbS), leading to erythrocyte sickling under deoxygenated conditions.
• Epidemiology: Most common in individuals of sub-Saharan African, Mediterranean, Middle Eastern, and Indian ancestry. In the U.S., affects approximately 1 in 365 African American births.
• Classification: HbSS (SCA, most severe), HbSC (often milder), HbS-$\beta$-thalassemia (variable severity based on $\beta^0$ vs $\beta^+$).

Pathophysiology

• Mechanism: Intracellular polymerization of deoxy-HbS causes rigid "sickle" shape, leading to vaso-occlusion (VOC) and chronic hemolytic anemia. Damage to the RBC membrane causes chronic endothelial activation, inflammation, and nitric oxide scavenging.
• Risk Factors: Dehydration, hypoxia, acidosis, infection, temperature extremes, stress.
• Protective Factors: Higher levels of Fetal Hemoglobin (HbF) which inhibits HbS polymerization; co-inheritance of alpha-thalassemia (reduces mean corpuscular hemoglobin concentration [MCHC]).

Clinical Presentation

Signs and Symptoms

• Cardinal Features: Vaso-occlusive pain crises (VOC), chronic hemolytic anemia, dactylitis (in infants), splenic sequestration, and stroke.
• Early Signs: Dactylitis (swelling of hands/feet) in children <3 years, pallor, fatigue.
• Advanced Signs: Chronic organ damage (pulmonary hypertension, nephropathy, retinopathy, avascular necrosis).
• Atypical Presentation: Acute Chest Syndrome (ACS) presenting as fever, cough, chest pain, and hypoxia.

Physical Examination

• Inspection: Jaundice (scleral icterus), delayed puberty, chronic leg ulcers, stunted growth.
• Palpation: Splenomegaly (usually early childhood, may lead to autosplenectomy later), hepatomegaly, bony tenderness.
• Special Tests: Transcranial doppler (TCD) for stroke risk screening; pulse oximetry.

Diagnostic Approach

History Taking

• Key Questions: Onset/duration of pain, triggers, history of fever, neurological changes, baseline Hb, transfusion history.
• Red Flags: Fever >38.5°C, new neurological deficit, severe headache, sudden drop in hemoglobin (aplastic crisis), respiratory distress.

Laboratory Tests

• First-Line: CBC with differential (low Hb, high reticulocytes), peripheral smear (sickled cells, Howell-Jolly bodies), chemistry panel (LDH, indirect bilirubin).
• Confirmatory: Hemoglobin electrophoresis or High-Performance Liquid Chromatography (HPLC) demonstrating predominant HbS.
• Monitoring: Annual baseline CBC, reticulocyte count, ferritin, renal function (BUN/Cr), and liver function tests.

Imaging

• Recommended: Chest X-ray for any suspected ACS, TCD ultrasound (pediatric age 2-16) for stroke screening.
• Advanced: MRI/MRA of the brain (if TCD abnormal or neuro symptoms), MRI of hips/femoral heads for avascular necrosis.

Management

Acute Management

• Immediate: Aggressive hydration (but avoid fluid overload), rapid pain management, supplemental $O_2$ (if $<92\%$).
• Emergency: Do not delay antibiotics for febrile patients (assume sepsis/bacteremia: Ceftriaxone).

Chronic Management

• Pharmacological:
  • Hydroxyurea: Standard of care for HbSS. Dosage: Start 15–20 mg/kg/day; titrate to maximum tolerated dose.
  • L-glutamine: Oral powder to reduce frequency of crises.
  • Voxelotor: HbS polymerization inhibitor (FDA approved for adults/pediatrics ≥12y).
  • Crizanlizumab: P-selectin inhibitor for reducing VOC frequency.
• Non-pharmacological: Prophylactic Penicillin V (BID) until age 5; routine immunizations (including pneumococcal, meningococcal, Hib, Influenza, COVID-19).

Treatment Algorithms

1. First-Line: Hydroxyurea (all patients HbSS, regardless of crisis frequency, starting at 9 months).
2. Second-Line: Chronic blood transfusion therapy (e.g., for stroke prevention or severe refractory ACS).
3. Refractory Cases: Hematopoietic stem cell transplantation (HSCT) or Gene therapy (e.g., Exagamglogene autotemcel).

Complications

• Common: VOC, cholelithiasis, proliferative retinopathy.
• Serious: Acute Chest Syndrome, stroke, splenic sequestration, priapism, osteomyelitis (Salmonella/Staphylococcus).
• Long-term: Chronic kidney disease (CKD), pulmonary hypertension, avascular necrosis (AVN).

Prognosis

• Factors: HbF levels, early enrollment in comprehensive care, adherence to hydroxyurea.
• Survival: Significantly improved with newborn screening and prophylactic penicillin; median survival now into the 5th/6th decade of life.

Special Populations

• Pediatric: Focus on neuroprotection (TCD) and infection prevention.
• Pregnancy: High risk. Hydroxyurea usually contraindicated (teratogenic). Manage with increased surveillance for preeclampsia/ACS and prophylactic transfusions.
• Comorbidities: High risk for iron overload (if chronically transfused); requires chelation therapy (e.g., Deferasirox).

Clinical Pearls

• Diagnostic: A normal Hb does not rule out sickle trait or other hemoglobinopathies; always confirm with electrophoresis.
• Treatment: In the ED, prioritize pain management. "Pain is what the patient says it is." Use IV opioids (Morphine/Hydromorphone) based on clinical assessment and pain scales.
• Pitfall: Assuming all fever is viral; assume bacterial infection until proven otherwise in sickle cell patients.

Key References

1. NHLBI: Evidence-Based Management of Sickle Cell Disease: Expert Panel Report.
2. ASH Guidelines: Management of Sickle Cell Disease (2020/2023 updates).
3. Blood Journal: Landmark studies on the 'Silent Cerebral Infarct Multi-Center Trial' (SIT).